Pfizer, Longevity Biotech Gero join hands to discover potential targets for fibrotic diseases

As part of this research collaboration, the companies will leverage Pfizer's expertise and Gero’s technology platform with the aim to identify genes and pathways linked to fibrotic diseases. Pfizer may advance the potential therapeutic targets and would be responsible for further preclinical and clinical development.

“Human data-driven drug discovery avoids the “preclinical trap” and has the potential to identify clinically relevant targets against human (not rodent) diseases. However, genetics-based target identification against age-related diseases is hindered by the irreversible component of human aging,” said Peter Fedichev, CEO of Gero. “Our technology platform allows us to separate irreversible effects of aging from reversible disease phenotypes to potentially identify the most actionable therapeutic targets.”

Gero will receive an upfront payment and is eligible to receive discovery milestone payments if the project progresses.

Read also: Pfizer Pentavalent Meningococcal Vaccine under USFDA review

“We are excited to work with Pfizer, one of the world’s leading biopharmaceutical companies, to potentially identify targets against fibrotic diseases, which have a large unmet need.” said Alex Kadet, CBO of Gero. “We believe that combining our platform technology with Pfizer’s extensive disease expertise has the potential to identify high-value targets in this disease area.”